← Eichor
Condition: Rrms Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Rrms

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
Phase 2 · 1 location(s) · Ari Green · NCT07510607Measuring Silent Disease Progression in Multiple Sclerosis With a Multimodal Approach
Phase N/A · 1 location(s) · Heinrich-Heine University, Duesseldorf · NCT06501950Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT05177523ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
Phase 4 · 14 location(s) · Novartis Pharmaceuticals · NCT06733922RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06267781A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsin
Phase 3 · 1 location(s) · University Hospital, Montpellier · NCT07189325A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
Phase 3 · 1 location(s) · Biocad · NCT07321093TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
Phase 2 · 5 location(s) · University Hospital, Strasbourg, France · NCT03910738Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
NA · 1 location(s) · Glostrup University Hospital, Copenhagen · NCT073181293D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME)
NA · 1 location(s) · University Hospital, Bordeaux · NCT05227092Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Di
NA · 2 location(s) · Centre Hospitalier Universitaire de Nīmes · NCT07292480A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms
Phase 1 · 35 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06220201Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05633875
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.